ALFA Filings
Every announcement, straight from the exchange
Announcement type
Time
28 announcements with these filters
JB Chemicals & Pharmaceuticals' amalgamation with Torrent Pharmaceuticals received NCLT sanction. The scheme will become effective upon filing with the Registrar of Companies.
Pradeep Kumar Singh and Suresh Bhise retired from the company. These changes in senior management are effective from June 30, 2026.
JB Chemicals clarified its audited financial results to the exchange. The board-approved results were signed by a director as authorized.
Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management effective June 12, 2026. Investors should note the departure of a key supply chain executive.
JB Chemicals & Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details company ESG performance, sustainability targets, and governance frameworks.
JB Chemicals & Pharmaceuticals filed its FY26 Business Responsibility and Sustainability Report. The filing highlights its ₹3889.89 Crore turnover and ESG progress for investor review.
JB Chemicals & Pharmaceuticals released its FY26 Integrated Annual Report, recording ₹4,148 Crore revenue. The company maintains strong growth momentum in domestic cardiology and international markets.
JB Chemicals & Pharmaceuticals announced its 50th AGM on June 17, 2026. Shareholders will consider a final dividend of ₹9.30 per share for the 2025-26 fiscal year.
J.B. Chemicals & Pharmaceuticals convened its 50th AGM for June 17, 2026. Shareholders will consider a final dividend of ₹9.30 per equity share.
JB Chemicals & Pharmaceuticals Ltd filed its Annual Secretarial Compliance Certificate for FY 2025-26. Practising Company Secretaries confirmed the company met all applicable SEBI regulatory requirements.
J.B. Chemicals & Pharmaceuticals fixed May 29, 2026, as the record date for final dividend eligibility. This determines which shareholders receive the 2025-26 payout.
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.
This was an operational reset quarter following Torrent Pharma's acquisition, marked by intentional portfolio pruning and alignment of trade practices with the new parent entity.
JB Pharma underwent an operational reset in Q4 FY26 following the Torrent Pharma acquisition. Revenue dipped 5% to ₹904cr due to the discontinuation of low-margin trade generics and distribution realignment.
JB Chemicals & Pharmaceuticals confirmed its status as a non-large corporate under SEBI debt-raising norms. The company reported zero outstanding long-term borrowings.
J.B. Chemicals recommended a final dividend of Rs. 9.30 (930%) per share for FY 2025-26. Payment is subject to shareholder approval at the upcoming AGM.
JB Pharma reported Q4 FY26 revenue of ₹904 Crore and PAT of ₹101 Crore. Muted performance followed an operational reset, with recovery expected by H1 FY27.
JB Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹904.2 Cr (-4.8% YoY) and net profit of ₹101.4 Cr (-30.4% YoY) for Q4 FY26.
J.B. Chemicals & Pharmaceuticals reported audited FY26 consolidated net profit of ₹709.47 Crore. The Board also recommended a final dividend of ₹9.30 per share.
JB Chemicals & Pharmaceuticals Limited has scheduled a Board Meeting on May 11, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 2026 and recommend a final dividend. The trading window remains closed until May 13, 2026.
JB Chemicals & Pharmaceuticals Limited has scheduled a board meeting for May 11, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. Trading window closure began on April 1, 2026.
J. B. Chemicals & Pharmaceuticals Ltd has scheduled a Board Meeting on May 11, 2026. The board will consider standalone and consolidated audited financial results for FY 2025-26 and recommend a final dividend.
J.B. Chemicals & Pharmaceuticals Limited announced that shareholders approved the Scheme of Amalgamation with Torrent Pharmaceuticals Limited. The resolution passed with a requisite majority via e-voting. This marks a significant regulatory milestone in the merger process between the two pharmaceutical entities.
J. B. Chemicals & Pharmaceuticals Ltd shareholders approved the Scheme of Amalgamation with Torrent Pharmaceuticals Limited during an NCLT-convened meeting. The resolution passed with a requisite majority of three-fourths in value. This marks a critical regulatory milestone in the merger process between the two pharmaceutical entities.
J.B. Chemicals & Pharmaceuticals Limited shareholders have approved the Scheme of Amalgamation with Torrent Pharmaceuticals Limited. The meeting, convened by the NCLT Ahmedabad Bench, saw the proposal passed with the requisite majority through e-voting. This marks a significant milestone in the merger process between the two pharmaceutical entities.
J.B. Chemicals & Pharmaceuticals Limited shareholders approved the Scheme of Amalgamation with Torrent Pharmaceuticals Limited during an NCLT-convened meeting. The resolution passed with a requisite majority via e-voting. The company will disclose final results separately to stock exchanges.
JB Chemicals & Pharmaceuticals Ltd submitted its quarterly certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The registrar, Datamatics Business Solutions, confirmed that securities received for dematerialization were processed and cancelled within the stipulated 15-day timeline.